Cargando…
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
BACKGROUND: PD-1/PD-L1 inhibitors are promising approaches for advanced Merkel cell carcinoma (MCC). Nevertheless, these inhibitors bear a high risk for induction of immune-related adverse events (irAEs), particularly flares of preexisting autoimmune diseases. Neurological irAEs of PD-1/PD-L1 inhibi...
Autores principales: | Zaremba, Anne, Chorti, Eleftheria, Jockenhöfer, Finja, Bolz, Saskia, Sirin, Selma, Glas, Martin, Becker, Jürgen C., Ugurel, Selma, Roesch, Alexander, Schadendorf, Dirk, Livingstone, Elisabeth, Hagenacker, Tim, Zimmer, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541996/ https://www.ncbi.nlm.nih.gov/pubmed/31142383 http://dx.doi.org/10.1186/s40425-019-0626-9 |
Ejemplares similares
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022) -
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy
por: Bolz, Saskia, et al.
Publicado: (2021) -
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020) -
CIDP, myasthenia gravis, and membranous glomerulonephritis – three autoimmune disorders in one patient: a case report
por: Bolz, Saskia, et al.
Publicado: (2018) -
Understanding the burden of refractory myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2019)